Ticker > Company >

Venus Remedies share price

Venus Remedies Ltd.

  57.12 K   78   7 NSE: VENUSREM BSE: 526953 SECTOR: Pharmaceuticals & Drugs

1657.00
+78.90 (5.00%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 1657

Today's Low

₹ 1547.85

52 Week High

₹ 2043.15

52 Week Low

₹ 423.7

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

2214.91 Cr.

Enterprise Value

2186.88 Cr.

No. of Shares

1.34 Cr.

P/E

19.58

P/B

3.1

Face Value

₹ 10

Div. Yield

0.6 %

Book Value (TTM)

₹  535.02

CASH

28.03 Cr.

DEBT

0 Cr.

Promoter Holding

41.76 %

EPS (TTM)

₹  84.64

Sales Growth

19.28%

ROE

15.53 %

ROCE

20.43%

Profit Growth

88.93 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year19.28%
3 Year12.66%
5 Year8.36%

Profit Growth

1 Year88.93%
3 Year50.79%
5 Year12.85%

ROE%

1 Year15.53%
3 Year10.43%
5 Year9.85%

ROCE %

1 Year20.43%
3 Year14.37%
5 Year12.14%

Debt/Equity

0

Price to Cash Flow

14.66

Interest Cover Ratio

0

CFO/PAT (5 Yr. Avg.)

1.30080510992618

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 41.76 0.00
Mar 2026 41.76 0.00
Dec 2025 41.76 0.00
Sep 2025 41.76 0.00
Jun 2025 41.76 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 50.79125247036% for the Past 3 years.
  • Company is virtually debt free.
  • Company’s PEG ratio is 0.220126007063295.
  • The company has an efficient Cash Conversion Cycle of 21.2333 days.
  • Company has a healthy liquidity position with current ratio of 2.5646.
  • The company has a good cash flow management; CFO/PAT stands at 1.30080510992618.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.80047100073773.

 Limitations

  • The company has shown a poor revenue growth of 12.6562374073932% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 137.13 192.65 179.95 259.01 178.8
Total Expenditure 119.2 162.81 143.23 199.58 142.24
Operating Profit 17.93 29.84 36.72 59.43 36.56
Other Income 2.72 1.68 2.41 4.63 2.55
Interest 0 0 0 0 0
Depreciation 5.95 5.92 6.32 6.5 6.51
Exceptional Items 0 0 0 0 0
Profit Before Tax 14.7 25.6 32.81 57.56 32.6
Tax 3.01 6.36 7.89 14.11 7.07
Profit After Tax 11.69 19.24 24.92 43.45 25.53
Adjusted EPS (Rs) 8.74 14.39 18.64 32.5 19.1

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 576.71 537.66 575.21 644.47 768.73
Total Expenditure 507.89 476.14 514.32 569.47 624.82
Operating Profit 68.82 61.53 60.89 75.01 143.92
Other Income 8.43 10.17 11.32 15.77 11.45
Interest 0 0 0 0 0
Depreciation 32.58 31.37 25.55 21.62 24.69
Exceptional Items 0 0 0 9.91 0
Profit Before Tax 44.67 40.33 46.65 79.08 130.67
Tax -4.32 11.36 16.15 26.51 31.36
Net Profit 48.99 28.96 30.5 52.56 99.31
Adjusted EPS (Rs.) 36.65 21.67 22.82 39.32 74.29

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 13.37 13.37 13.37 13.37 13.37
Total Reserves 436.05 464.68 495.22 576.13 676.26
Borrowings 38.68 38.68 38.68 0 0
Other N/C liabilities 7.27 19.49 21.18 18.48 28.2
Current liabilities 82.61 72.67 72.81 105.23 158.23
Total Liabilities 577.98 608.89 641.26 713.21 876.06
Assets
Net Block 224.67 199.68 202.76 214.14 214.62
Capital WIP 25.23 26.1 21.08 26.39 51.36
Intangible WIP 0 0 0 0 0
Investments 0.14 0.14 0.16 54.96 163.95
Loans & Advances 61.96 62.55 51.76 33.56 35.41
Other N/C Assets 1.57 2.23 4.5 3.21 4.91
Current Assets 264.41 318.19 361 380.95 405.8
Total Assets 577.98 608.89 641.26 713.21 876.06
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 44.67 40.33 46.65 69.16 130.67
Adjustment 24.83 22.25 19.36 16.12 17.35
Changes in Assets & Liabilities -28.5 -34.53 -15.15 12.74 37.33
Tax Paid 0 0 -15.48 -14.92 -34.27
Operating Cash Flow 41 28.05 35.38 83.1 151.09
Investing Cash Flow -16.75 -50.81 -6.94 -76.2 -181.57
Financing Cash Flow -9.13 0 0 0 -1.39
Net Cash Flow 15.12 -22.76 28.44 6.9 -31.86

Corporate Actions

Investors Details

PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
promoters 41.76 41.76 41.76 41.76 41.76
manu chaudhary - - - - 11.73
pawan chaudhary 12.82 12.82 12.82 12.82 12.82
sunev pharma solutions pv... - - - - 17.21
manu chaudhary 11.73 11.73 11.73 11.73 -
sunev pharma solutions pr... - - - 17.21 -
sunev pharma solutions li... 17.21 17.21 17.21 - -
PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
investors 58.24 58.24 58.24 58.24 58.24
acadian emerging markets ... 1.10 1.10 1.10 1.10 1.10
investor education & prot... - - - - 1.00
llp 0.23 2.05 2.25 - 2.13
nisarg ajaykumar vakharia... - - - 1.05 1.05
rajni tarun jain 1.50 1.50 - 1.42 1.42
tikri partners llp - 1.78 1.96 1.97 1.97
investor education and pr... - 1.00 1.00 1.00 -
k.b.shekar 1.94 1.88 - 1.42 -
k.b.shekar               ... - - 1.42 - -
nisarg ajaykumar vakharia... - - 1.05 - -
rajni tarun jain         ... - - 1.42 - -
anurag jain 1.12 - - - -
investor education and pr... 1.00 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2026
Annual Report 2025
Annual Report 2021
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Venus Remedies informs about newspaper publication 27 Jul, 1:15 PM Venus Remedies - Quaterly Results 21 Jul, 12:00 AM Venus Remedies touches roof on securing renewal of DSIR R&D recognition for VMRC 5 Jun, 11:22 AM Venus Remedies secures renewal of DSIR R&D recognition for VMRC 4 Jun, 5:45 PM Venus Remedies touches roof on getting marketing authorization from SFDA for Plerixafor 22 May, 2:35 PM Venus Remedies gets marketing authorization from SFDA for Plerixafor 22 May, 2:22 PM Venus Remedies informs about updates 4 May, 2:13 PM Venus Remedies - Quaterly Results 30 Jan, 12:00 AM Venus Remedies informs about board meeting 19 Jan, 1:04 PM Venus Remedies soars on getting marketing authorization in Indonesia for Ceftazidime + Avibactam 9 Jan, 10:12 AM Venus Remedies gets marketing authorization in Indonesia for Ceftazidime + Avibactam 9 Jan, 9:41 AM Venus Remedies informs about press release 8 Dec, 4:05 PM Venus Remedies informs about update on resolution of income tax matters 1 Dec, 12:23 PM Venus Remedies informs about clarification on movement in volume 20 Nov, 1:58 PM Venus Remedies informs about press release 12 Nov, 3:17 PM Venus Remedies informs about updates 28 Oct, 5:37 PM Venus Remedies informs about updates 11 Sep, 2:08 PM Venus Remedies - Quaterly Results 1 Aug, 5:00 PM Venus Remedies - Quaterly Results 1 Aug, 5:00 PM Venus Remedies - Quaterly Results 1 Aug, 5:00 PM Venus Remedies informs about confirmation certificate 8 Jul, 12:20 PM Venus Remedies - Quaterly Results 26 May, 10:29 PM Venus Remedies - Quaterly Results 26 May, 10:29 PM Venus Remedies secures Ukrainian GMP renewal 22 May, 2:30 PM USFDA grants QIDP Designation to Venus Remedies’ investigational product VRP-034 17 Apr, 12:59 PM Venus Remedies sings license agreement with lnfex Therapeutics to develop MET-X 25 Feb, 12:43 PM Venus Remedies informs about press release 25 Feb, 10:27 AM Venus Remedies - Quaterly Results 4 Feb, 9:02 PM Venus Remedies - Quaterly Results 4 Feb, 9:02 PM Venus Remedies gets GMP certification for antibiotic-carbapenem facility 31 Dec, 2:45 PM Venus Remedies secures Marketing Authorization in Philippines 6 Dec, 3:51 PM Venus Remedies gets nod to establish wholly owned subsidiary in Hungary 30 Nov, 3:17 PM Venus Remedies informs about press release 5 Nov, 11:37 AM Venus Remedies secures Malaysian PIC/S GMP approval for pre-filled syringe facility 5 Nov, 10:44 AM Venus Remedies - Quaterly Results 29 Oct, 9:59 PM Venus Remedies - Quaterly Results 29 Oct, 9:59 PM Venus Remedies informs about closure of trading window 24 Sep, 5:27 PM Venus Remedies - Quaterly Results 13 Aug, 7:28 PM Venus Remedies informs about postponement of board meeting 17 Jul, 10:16 AM Venus Remedies informs about closure of trading window 26 Jun, 10:05 AM Venus Remedies gets oncology tender from PAHO 19 Jun, 10:50 AM Venus Remedies informs about updates 13 Jun, 12:21 PM Venus Remedies secures award for antibiotic product Ceftriaxone 1gm from UNICEF 13 Jun, 9:50 AM Venus Remedies informs about newspaper publication 1 Jun, 3:03 PM Venus Remedies - Quaterly Results 30 May, 8:54 PM Venus Remedies informs about disclosure 1 Apr, 12:58 PM Venus Remedies gets marketing authorisations from Ukraine for three cancer drugs 18 Mar, 4:47 PM Venus Remedies obtains Marketing Authorizations for range of essential oncology drugs in Ukraine 9 Mar, 3:39 PM Venus Remedies awarded first incentive of Rs 7.50 crore under PLI scheme 6 Mar, 10:30 AM Venus Remedies informs about press release 6 Mar, 9:33 AM

Venus Remedies Stock Price Analysis and Quick Research Report. Is Venus Remedies an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Venus Remedies. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Venus Remedies has a PE ratio of 19.4585628309551 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Venus Remedies has ROA of 12.4976% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Venus Remedies has a Current ratio of 2.5646.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Venus Remedies has a ROE of 15.5279%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Venus Remedies has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Venus Remedies has reported revenue growth of 19.2816% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Venus Remedies for the current financial year is 18.7210986155433%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Venus Remedies is Rs 10 and the yield is 0.6035%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Venus Remedies is Rs 84.6414. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Venus Remedies in Ticker for free. Also, one can get the intrinsic value of Venus Remedies by using Valuation Calculators, which are available with a Finology ONE subscription. 

Venus Remedies FAQs

Q1. What is Venus Remedies share price today?
Ans: The current share price of Venus Remedies is Rs 1647.

Q2. What is the market capitalisation of Venus Remedies?
Ans: Venus Remedies has a market capitalisation of Rs 2201.5429236 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Venus Remedies?
Ans: The PE ratio of Venus Remedies is 19.4585628309551 and the P/B ratio of Venus Remedies is 3.07840225128958, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Venus Remedies share?
Ans: The 52-week high share price of Venus Remedies is Rs 2044.3, and the 52-week low share price of Venus Remedies is Rs 424.

Q5. Does Venus Remedies pay dividends?
Ans: Currently, Venus Remedies pays dividends. Dividend yield of Venus Remedies is around 0.6035%.

Q6. What are the face value and book value of Venus Remedies shares?
Ans: The face value of Venus Remedies shares is Rs 10, while the book value per share of Venus Remedies is around Rs 535.0178. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Venus Remedies?
Ans: Venus Remedies has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Venus Remedies?
Ans: The ROE of Venus Remedies is 15.5279% and ROCE of Venus Remedies is 20.4319%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Venus Remedies a good buy for the long term?
Ans: The Venus Remedies long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Venus Remedies undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Venus Remedies appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Venus Remedies’s financials?
Ans: You can review Venus Remedies’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Venus Remedies
X